IDEA #04JB1F Cardiolyse - prevention and management of cardiovascular conditions

Value proposition At Cardiolyse we strive to solve one of the most challenging health problems - heart and emotional disorders resulting from the fatigue/chronic fatigue of active ageing people, particularly for the 40-60 age group. The ultimate goal is to enable health self-management, which will empower people to extend their enjoyable lifespan. Our ultimate vision is to be an essential part of the population’s health monitoring and prevention, providing the best prognostic tools for managing heart health and leading the prevention of cardiovascular diseases (CVDs), chronic fatigue and burnout. We've done a lot to prove the efficacy and outstanding capability of our ML algorithms, we've been collaborating for 3 years with University of Oxford’s Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU) and China Kadoori Biobank analysing study's 0,5M data). We work with wearable makers, corporate well-being programs providers, insurance companies (to reduce premiums for policyholders who keep their scores at pre-defined levels), national health services and their suppliers (to reducing escalating healthcare costs and increasing access to preventive care for the rural communities, keeping people out of the hospitals) and telemedicine and telehealth providers. The challenge Traditional clinical heart diagnostics specialise in the monitoring of heart conditions during treatment of heart disorders with limited attention to heart health improvement and predictive CVD prevention. Cardio problems dramatically reduce the quality of life (especially in the 40+ age group, who are mostly at risk of lifestyle related heart disorders). The key challenges are: (i) How to extend healthy ageing as long as possible, and; (ii) How to make the prevention personalized? The solution We are commercialising decades of research carried out at the Ukrainian Academy of Sciences. We have built the first cloud-based commercial solution that takes ECG data beyond current diagnostics by providing monitoring, lifestyle assessment and unique prognostics for potential heart disorders. We offer to B2B partners a cloud-based ECG & HRV data analytics platform that actively monitors their end-users’ heart and emotional wellbeing. Each heart parameter is placed on a scale from normal to pathological; they are then grouped into blocks for daily health management (giving a ‘Heart Wellbeing Score’). Crucially, Cardiolyse’s highly accurate and comprehensive algorithms (analysing all known biomarkers) are able to predict cardiac-related events up to 3 months in advance of symptoms. They also allow tracking heart reactions and functional capacity of a body to everyday activities, enabling a broad range of personalized diagnostics and recommendations such as: Preventive - regarding the person’s functional state, stamina, heart muscle state, psychological emotional state, heart biological age and stress levels. Diagnostic - formulated in specific disease terms for a medical professional, and covering such conditions as ischemia, arrhythmias, hypertrophy of the heart chambers, conduction defects. Prognostic - a forecast (up to 3 months) of the heart events (such as heart attacks, strokes). Proprietary parameters are very sensitive to subtle changes of physiological state showing how lifestyle and routine (food, cardio drugs, rest, stress, workouts, etc.) impact the heart health. Market size, trends and drivers We are part of the Lifestyle Wellness Market $ 574bn - Healthy eating, nutrition and weight loss, annual growth rate of 5.4% $ 446bn - Fitness and mind-body, annual growth rate of 4,5% $ 432bn - Preventive/personalised health, annual growth rate of 21.2% $ 40bn - Workplace wellness, annual growth rate of 8.9% With the latter, our segment is the fastest growing in the US and globally . Sources: SRI International - Global Wellness Summit (2013); PWC (March 2015); TechNavio - Global Connected Health M2M Market 2015-2019 Size and Forecast; ; Statista - Digital Market Outlook – 2015 We are a part of the big emerging trend of moving healthcare from the “sick care approach” to the informed “heart health management approach” by partnering with players, whose focus is disease prevention through personalised recommendations for lifestyle changes and diet. The world is on the edge of a global chronic disease epidemic requiring fundamental lifestyle changes by the majority of the society, as well as structural changes in the approach and infrastructure of healthcare systems. Competitive landscape Although Cardiolyse has a number of competitors, it has three major, unique, and hard to emulate competitive advantages. Firstly, it is the only company that offers prognostics and prevention analysis. Secondly, it is an input device-agnostic platform that provides users with the flexibility to interoperate with various wearables and fitness apps, unlike competitors relying on their own proprietary devices. Thirdly, it is the most comprehensive ECG & HRV data processing platform out there. Business model & technology validation Target markets: We provide access to our cloud-based data processing platform (via a dedicated API), which offers predictive and remote monitoring services for B2B players in the preventive eco-system. We are focusing our R&D efforts on the population health, adding new biomarkers, as well as developing predictive ECG rules for Big Data analysis to forecast the emergence of an elevated risk group. This allows offering unique commercial Big Data Analysis package to insurance companies and to the national health services. We work with the Nuffield Department for Population Studies (University of Oxford), which conducts our technology validation on a large sample (0.5m) with China Kadoorie Biobank. Our second trial finished with enough validation for striking a commercial deal with partners in India, as well as it opens up opportunities in other emerging markets (where certification is not required). Our revenue comes from B2B SaaS and subscription sales. They include one-off on boarding, license and usage fees (tagged to a number of analysis carried out). Our profit margins exceed 50%. Our core tech team is developing deep technology (algorithms) to make forecast and recommendations even more accurate. The web interface and a mobile application development is outsourced.